SPYH:F:F-SSgA SPDR ETFs Europe II Public Limited Company - SPDR MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 222.3

Change

+4.15 (+1.90)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

+2.60 (+0.47%)

USD 108.00B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.60 (+1.15%)

USD 105.67B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.64 (+1.14%)

USD 104.83B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.31 (+2.02%)

USD 62.86B
VUSA:F Vanguard Funds Public Limited ..

+0.83 (+0.85%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+1.40 (+0.60%)

USD 49.04B
XJSE:F Xtrackers II - Japan Governmen..

-0.04 (-0.59%)

USD 41.48B
0ZC:F Zscaler Inc

+12.10 (+6.94%)

USD 37.92B
BSND:F Danone SA

+0.40 (+2.92%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

N/A

USD 24.77B

ETFs Containing SPYH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.02% 72% C 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.02% 72% C 65% D
Trailing 12 Months  
Capital Gain 3.30% 42% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.30% 40% F 45% F
Trailing 5 Years  
Capital Gain 74.79% 49% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.79% 49% F 39% F
Average Annual (5 Year Horizon)  
Capital Gain 9.57% 66% D+ 63% D
Dividend Return 9.57% 64% D 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.93% 76% C+ 94% A
Risk Adjusted Return 120.63% 97% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike